10.3389/fphys.2019.00428 65
Currently, effective therapeutic agents for MASLD are focused on multiple potential targets, with multi-target, multi-pathway therapeutic measures and targeted agents for key aspects of the target genes or metabolic pathways will also be applied in the clinic
Chen KY, Muniyappa R, Abel BS, et al
*Correspondence: Mlanie Morin-Brureau [email protected] This article was submitted to Non-Neuronal Cells, a section of the journal Frontiers in Cellular Neuroscience Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Mary Watanabe Person So we've done nine so far
Notably, because 0.5-mg semaglutide is already recognized as a highly efficacious dose, demonstrating additional benefit in patients who were stably treated at this level underscores the potential clinical value of escalation
